ArticleTherapeutic advances in gastroenterology2019
Association of serum albumin level with incidence and mortality of overt hepatic encephalopathy in cirrhosis during hospitalization.
Article in Therapeutic advances in gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Risk prediction models for hepatic encephalopathy in patients with liver cirrhosis: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Use of human albumin infusion in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials.Hepatology international · 2022Pooled it
- Using machine learning methods to predict 28-day mortality in patients with hepatic encephalopathy.BMC gastroenterology · 2023Trial
- Article
- Simple scoring model for predicting overt hepatic encephalopathy in geriatric cirrhosis: A multicenter retrospective cohort study.Metabolic brain disease · 2025Article
- Predictors of Mortality in Patients with Hepatic Encephalopathy: A Retrospective Analysis.Cureus · 2025Article
- Predicting the Impact of Polysulfone Dialyzers and Binder Dialysate Flow Rate on Bilirubin Removal.Bioengineering (Basel, Switzerland) · 2024Article
- Efficacy of albumin use in decompensated cirrhosis and real-world adoption in Australia.JGH open : an open access journal of gastroenterology and hepatology · 2024Review
- Physiological network approach to prognosis in cirrhosis: A shifting paradigm.Physiological reports · 2024Review
- Review
- Use of albumin infusion for cirrhosis-related complications: An international position statement.JHEP reports : innovation in hepatology · 2023Article
- Expert perspectives for the pharmacist on facilitating and improving the use of albumin in cirrhosis.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2023Review
- Psychometric tests, critical flicker frequency, and inflammatory indicators in covert hepatic encephalopathy diagnosis.Hepatology forum · 2023Article
- Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions.World journal of gastroenterology · 2022Review
- A simple covert hepatic encephalopathy screening model based on blood biochemical parameters in patients with cirrhosis.PloS one · 2022Article
- Analysis of the Dose-Response Relationship Between the International Normalized Ratio and Hepatic Encephalopathy in Patients With Liver Cirrhosis Using Restricted Cubic Spline Functions.Frontiers in public health · 2022Article
- Human albumin infusion strategy in liver cirrhosis: liberal or restrictive?Annals of translational medicine · 2021Article
- Minimal Hepatic Encephalopathy and Biejia-Ruangan Are Associated with First Hospital Readmission in Nonalcoholic Cirrhosis Patients.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Low Serum 25-Hydroxy Vitamin D (25-OHD) and Hepatic Encephalopathy in HCV-Related Liver Cirrhosis.International journal of hepatology · 2021Article
- Hepatic Encephalopathy: Diagnosis and Management.Journal of translational internal medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatic encephalopathy (HE) is a serious complication of cirrhosis. Decreased serum albumin (ALB) level may facilitate the development of HE and accelerate the death of cirrhotic patients with HE. Recent evidence also suggests that human albumin infusion may reduce the incidence of HE and improve the outcomes of cirrhotic patients. This study aimed to explore the association of serum ALB level with the development of overt HE and HE-associated mortality during hospitalization.
methodsCirrhotic patients admitted to our hospital between January 2010 and February 2019 were screened. Independent predictors for HE were identified by logistic regression analyses. Odds ratio (OR) with 95% confidence interval (95% CI) was calculated. Area under curve (AUC) was calculated by receiver operator characteristic curve analyses.
resultsOf the 2376 included patients with cirrhosis but without HE at admission, 113 (4.8%) developed overt HE during hospitalizations. ALB level (OR = 0.878, 95% CI = 0.834-0.924) was an independent risk factor for development of overt HE. AUC of ALB level for predicting the development of overt HE was 0.770 (95% CI = 0.752-0.787,
conclusionsDecreased serum ALB level may be associated with higher risk of overt HE and HE-associated mortality during hospitalizations in cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.